Physician profile
Patrick C Marvil
NPI 1235629304
$876.58
in general payments reported to CMS, 2019-2025
22 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.21 · 2022: $262 · 2023: $160 · 2024: $286 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119.98 | 2021-2025 | |
| Novo Nordisk INC | $88.08 | 2022-2024 | Wegovy |
| Medtronic, INC. | $71.86 | 2022-2024 | Intellis Adaptivestim |
| Abbott Laboratories | $68.25 | 2024-2025 | Freestyle Libre 3 |
| Amgen INC. | $65.61 | 2022-2025 | Krystexxa, Evenity |
| Pfizer INC. | $62.57 | 2022-2024 | |
| Glaxosmithkline, LLC. | $62.27 | 2021-2023 | Shingrix |
| Janssen Pharmaceuticals, INC | $50.47 | 2022 | |
| Dexcom, INC. | $41.10 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $32.22 | 2024 | Flumist Quadrivalent |
| Exact Sciences Corporation | $23.98 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $22.96 | 2024 | Keveyis |
| Lilly USA, LLC | $22.10 | 2022 | |
| Acadia Pharmaceuticals INC | $19.97 | 2023 | Daybue |
| Biohaven Pharmaceutical Holding Company LTD. | $19.59 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $19.38 | 2023 | |
| Hologic Sales and Service, LLC | $16.82 | 2022 | |
| Gilead Sciences, INC. | $15.55 | 2022 | |
| Horizon Therapeutics Plc | $14.71 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $14.51 | 2023 | |
| Corcept Therapeutics | $13.48 | 2024 | Korlym |
| Linus Health, INC. | $11.12 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Marvil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.